News Conference News TCT 2017 Intermediate-Risk TAVR Substantially More Cost-effective Than Surgery Yael L. Maxwell October 31, 2017
News Daily News FDA Expands CoreValve Indication to Include Intermediate-Risk Patients Michael O'Riordan July 10, 2017
News Conference News TVT 2017 Lagging Behind: Guidelines Can’t Keep Up With Growing TAVR Evidence Base Michael O'Riordan June 17, 2017
News Daily News FDA Expands Sapien 3 Indication to Aortic, Mitral Valve-in-Valve Replacement Michael O'Riordan June 06, 2017